Boosting Immune Cells to Fight Cancer
Bhlhe40 Regulation of T Cell Function During Cancer Immunotherapy
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-11098667
This research looks at how a specific protein helps immune cells called T cells work better against cancer, especially with immunotherapy treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11098667 on ClinicalTrials.gov |
What this research studies
Our immune system's T cells are vital for fighting cancer, especially when supported by treatments like immunotherapy. This project explores a key protein, Bhlhe40, that helps these T cells stay active and effective against tumors. We've seen in early models that Bhlhe40 is essential for T cells to successfully eliminate cancer. The goal is to understand exactly how Bhlhe40 supports both CD4 and CD8 T cells, which are both critical for a strong anti-cancer response. This knowledge could lead to new ways to make immunotherapies more powerful for patients.
Who could benefit from this research
Good fit: Patients with cancers that are treated with or could benefit from immunotherapies, such as melanoma or sarcoma, might eventually benefit from this research.
Not a fit: Patients whose cancers do not respond to or are not treated with immunotherapy may not directly benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to new strategies to improve how well cancer immunotherapies work for patients.
How similar studies have performed: This research builds upon recent discoveries by the team, indicating a novel and promising direction for enhancing existing cancer immunotherapies.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GUBIN, MATTHEW M. — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: GUBIN, MATTHEW M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.